Animal Model Market

Animal Model Market Forecast and Outlook 2025 to 2035

The global animal model market is valued at USD 2.8 billion in 2025 and is slated to reach USD 5.1 billion by 2035, recording an absolute increase of USD 2.3 billion over the forecast period. This translates into a total growth of 82.1%, with the market forecast to expand at a compound annual growth rate (CAGR) of 6.2% between 2025 and 2035. The overall market size is expected to grow by nearly 1.8X during the same period, supported by increasing pharmaceutical research, growing biotechnology development, and rising adoption of preclinical testing services across diverse drug discovery and biomedical research applications.

Quick Stats for Animal Model Market

• Animal Model Market Value (2025): USD 2.8 billion
• Animal Model Market Forecast Value (2035): USD 5.1 billion
• Animal Model Market Forecast CAGR: 6.2%
• Leading Species in Animal Model Market: Mice (52.0%)
• Key Growth Regions in Animal Model Market: North America, Europe, and Asia Pacific
• Key Players in Animal Model Market: The Jackson Laboratory, Charles River, Envigo, Taconic, GemPharmatech, InVivos

Between 2025 and 2030, the animal model market is projected to expand from USD 2.8 billion to USD 3.8 billion, resulting in a value increase of USD 1.0 billion, which represents 43.5% of the total forecast growth for the decade. This phase of development will be shaped by increasing drug discovery activities, rising biomedical research funding, and growing adoption of specialized animal models in pharmaceutical development operations. Service providers are expanding their breeding capabilities to address the growing demand for genetically modified models and enhanced research reliability.

Animal Model Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 2.8 billion
Forecast Value in (2035F)	USD 5.1 billion
Forecast CAGR (2025 to 2035)	6.2%

From 2030 to 2035, the market is forecast to grow from USD 3.8 billion to USD 5.1 billion, adding another USD 1.3 billion, which constitutes 56.2% of the overall ten-year expansion. This period is expected to be characterized by the expansion of advanced genetic engineering systems, the integration of precision breeding technologies, and the development of enhanced disease models for major pharmaceutical companies. The growing adoption of personalized medicine research and efficient preclinical protocols will drive demand for animal models with enhanced genetic precision and improved translational relevance.

Between 2020 and 2025, the animal model market experienced robust recovery growth, driven by increasing pharmaceutical research demand and growing recognition of animal models as essential components for drug development and biomedical research applications. The market developed as pharmaceutical companies and research institutions recognized the potential for specialized animal models to enhance research outcomes while maintaining regulatory compliance and improving development timelines. Technological advancement in genetic engineering and breeding systems began emphasizing the critical importance of maintaining model quality and operational efficiency in biomedical research operations.

Why is the Animal Model Market Growing?

Market expansion is being supported by the increasing global pharmaceutical research and the corresponding need for reliable preclinical models that can provide predictive data while supporting diverse drug development applications across various research environments. Modern pharmaceutical companies and research institutions are increasingly focused on implementing model solutions that can accelerate discovery timelines, enhance research validity, and provide consistent performance in preclinical studies. Animal models' proven ability to deliver translational research capabilities, regulatory compliance support, and diverse application potential make them essential components for contemporary drug development operations and biomedical research solutions.

The growing emphasis on precision medicine and biotechnology innovation is driving demand for animal models that can support specialized research applications, improve disease modeling, and enable efficient research operations across varying pharmaceutical development configurations. Research preference for models that combine genetic precision with research reliability and regulatory acceptance is creating opportunities for innovative animal model implementations. The rising influence of oncology research and CNS drug development is also contributing to increased adoption of animal models that can provide advanced research capabilities without compromising ethical standards or research quality.

Opportunity Pathways - Animal Model Market

The animal model market is poised for robust growth and transformation. As pharmaceutical companies and research institutions across both developed and emerging markets seek research models that are precise, reliable, compliant, and translatable, animal model systems are gaining prominence not just as research tools but as strategic components for discovery acceleration, research excellence, regulatory compliance, and innovation advancement.

Rising pharmaceutical research and biotechnology development in North America, Europe, and Asia Pacific amplify demand, while providers are picking up on innovations in genetic engineering technologies and breeding enhancement methods.

Pathways like genetically modified models, specialized disease applications, and integrated research services promise strong margin uplift, especially in developed markets. Geographic expansion and research diversification will capture volume, particularly where pharmaceutical research is growing or biomedical infrastructure requires enhancement. Quality pressures around genetic precision, research reliability, regulatory compliance, and translational relevance give structural support.

• Pathway A - Genetically Modified & Designer Models. Research institutions increasingly require animal models that offer specific genetic modifications and disease characteristics. Providers who specialize in custom genetic engineering or enhance model precision can command a premium. Expected revenue pool: USD 714.0-857.0 million
• Pathway B Specialized Disease Models & Applications. Enhanced model systems -- oncology models, CNS applications, metabolic research -- improve research relevance and discovery outcomes. Opportunity: USD 571.0-691.0 million
• Pathway C Integrated Research Services & CRO Solutions. Direct integration with pharmaceutical research, comprehensive study services, and regulatory support optimize research delivery and enhance client relationships. Systems with stronger service integration will allow premium positioning. Revenue lift: USD 446.0-571.0 million
• Pathway D - Personalized Medicine & Biomarker Research. Extending reach into precision medicine applications, biomarker studies, and therapeutic targeting research. Pharmaceutical companies seek model providers who deliver specialized, translatable solutions. Pool: USD 404.0-530.0 million
• Pathway E Emerging Market Expansion. Strong growth in developing pharmaceutical markets, research infrastructure development, and biotechnology expansion. Local partnerships and breeding facilities help penetration. Expected upside: USD 357.0-446.0 million
• Pathway F - Regulatory & Compliance Services. Regulatory guidance, compliance support, and quality assurance help researchers ensure study validity and regulatory acceptance. Service approaches benefit from long-term partnerships. USD 250.0-321.0 million
• Pathway G Ethical & Alternative Solutions. Advanced welfare standards, refinement approaches, and alternative model development create competitive advantages and ethical benefits. Pool: USD 214.0-286.0 million

Segmental Analysis

The market is segmented by species, application, and service. By species, the market is divided into mice, rats, and zebrafish/others. By application, it covers oncology, CNS/metabolic, and others. By service, it is segmented into breeding, CRO studies, and custom/others. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

By Species, the Mice Segment Accounts for 52.0% Market Share

The mice species is projected to account for 52.0% of the animal model market in 2025, reaffirming its position as the leading research model category. Research institutions and pharmaceutical companies increasingly utilize mice models for their genetic similarity, established research protocols, and proven research validity across oncology studies, CNS research, and drug development applications. Mice species' established breeding procedures and consistent research outcomes directly address the industry requirements for reliable research models and regulatory compliance in diverse research environments.

This species segment forms the foundation of current market operations, as it represents the model with the greatest research versatility and established research infrastructure across multiple research applications and study scenarios. Provider investments in enhanced genetic modification and breeding optimization continue to strengthen adoption among research institutions. With researchers prioritizing model reliability and research translatability, mice operations align with both research objectives and regulatory requirements, making them the central component of comprehensive animal model strategies.

By Application, the Oncology Segment Accounts for 41.0% Market Share

Oncology applications are projected to represent 41.0% of animal model demand in 2025, underscoring their critical role as the primary research requirement for cancer drug development and therapeutic research applications. Pharmaceutical researchers prefer oncology models for their disease relevance, translational potential, and ability to provide predictive data while supporting drug discovery and clinical development requirements. Positioned as essential application for modern pharmaceutical research, oncology offers both research advantages and development benefits.

The segment is supported by continuous innovation in cancer modeling and the growing availability of specialized tumor models that enable diverse research applications with enhanced translational capabilities. Additionally, researchers are investing in model optimization to support drug discovery and therapeutic development delivery. As cancer research becomes more prevalent and therapeutic development requirements increase, oncology applications will continue to dominate the application market while supporting advanced therapeutic positioning and drug development strategies.

By Service, the Breeding Segment Accounts for 46.0% Market Share

Breeding services are projected to represent 46.0% of animal model services in 2025, underscoring their critical role as the primary service requirement for research model supply and genetic maintenance. Research institutions prefer breeding services for their model availability, genetic consistency, and ability to provide reliable supply while supporting research continuity and quality assurance requirements. Positioned as essential service for modern research operations, breeding offers both supply advantages and quality benefits.

The segment is supported by continuous innovation in breeding technology and the growing availability of specialized genetic methods that enable enhanced model quality with improved research reliability. Additionally, providers are investing in breeding optimization to support model quality and supply consistency delivery. As research demand becomes more prevalent and model quality requirements increase, breeding services will continue to dominate the service market while supporting advanced research efficiency and model quality strategies.

What are the Drivers, Restraints, and Key Trends of the Animal Model Market?

The animal model market is advancing rapidly due to increasing pharmaceutical research and growing adoption of specialized research models that provide enhanced translational relevance and regulatory compliance across diverse biomedical applications. However, the market faces challenges, including ethical considerations, regulatory complexity, and varying research requirements across different therapeutic environments. Innovation in genetic engineering and alternative approaches continues to influence model development and market expansion patterns.

Rising Pharmaceutical Research and Drug Development Pipeline

The growing expansion of pharmaceutical research and drug development activities is enabling providers to develop animal models that provide superior research validity, enhanced translational relevance, and reliable predictive capability in pharmaceutical research environments. Advanced breeding systems provide improved model quality while allowing more effective research delivery and consistent study outcomes across various therapeutic applications and research requirements. Providers are increasingly recognizing the competitive advantages of specialized model capabilities for market positioning and pharmaceutical industry targeting.

Genetic Engineering Innovation and Precision Breeding Drive Market Development

Modern animal model providers are incorporating advanced genetic engineering methods and precision breeding systems to enhance model relevance, improve research outcomes, and ensure consistent performance delivery to pharmaceutical companies and research institutions. These technologies improve research standards while enabling new applications, including personalized medicine models and disease-specific research tools. Advanced genetic integration also allows providers to support premium service positioning and research optimization beyond traditional animal supply.

Analysis of the Animal Model Market by Key Countries

Country	CAGR (2025-2035)
USA	7.1%
Mexico	6.7%
Germany	6.3%
France	6.2%
UK	6.0%
South Korea	5.9%
Japan	5.8%

The animal model market is experiencing robust growth globally, with the USA leading at a 7.1% CAGR through 2035, driven by extensive pharmaceutical research expansion, advanced biotech infrastructure investments, and significant adoption of precision medicine technologies. Mexico follows at 6.7%, supported by growing research development, rapid pharmaceutical modernization, and growing adoption of biotechnology research systems. Germany shows growth at 6.3%, emphasizing quality standards and pharmaceutical research capabilities. France and UK record strong growth, focusing on biomedical research development and drug discovery optimization. South Korea demonstrates 5.9% growth, supported by biotechnology trends and pharmaceutical research expansion. Japan demonstrates 5.8% growth, supported by advanced research but facing regulatory complexity.

The report covers an in-depth analysis of 40+ countries; seven top-performing countries are highlighted below.

United States Demonstrates Pharmaceutical Research Innovation

The U.S. market emphasizes advanced model features, including precision genetic control and integration with comprehensive pharmaceutical platforms that manage research optimization, discovery acceleration, and regulatory applications through unified animal model systems. The country demonstrates strong growth at 7.1% CAGR, driven by pharmaceutical innovation, biotech expansion, and emerging precision medicine applications that support animal model system integration. American research institutions prioritize research effectiveness with animal models delivering consistent study performance through advanced genetic capabilities and specialized research adaptation.

Technology deployment channels include major pharmaceutical companies, specialized research institutions, and biotech procurement programs that support professional applications for complex drug discovery and biomedical research applications. Pharmaceutical platform integration capabilities with established research systems expand market appeal across diverse research requirements seeking discovery benefits and regulatory compliance. The resilient pharmaceutical sector and expanding biotech capacity additions create sustained demand, while innovative applications in gene therapy research open new growth avenues.

Performance Metrics:

• Pharmaceutical research facilities in Massachusetts, California, and North Carolina leading animal model adoption for drug discovery applications
• Specialty research service channels maintaining 75% market share for complex pharmaceutical integration applications
• Drug discovery programs supporting 47% of animal model acquisitions across pharmaceutical and research facilities
• Pharmaceutical platform compatibility with major research systems driving procurement selection criteria

Mexico Maintains Research Growth

Mexico's expanding research market demonstrates sophisticated animal model adoption with documented research effectiveness in pharmaceutical applications and biomedical facilities through integration with existing research systems and pharmaceutical infrastructure. The country leverages growing research development and pharmaceutical integration to maintain strong growth at 6.7% CAGR. Research centers, including Mexico City, Guadalajara, and Monterrey, showcase premium applications where animal model systems integrate with comprehensive research platforms and pharmaceutical management systems to optimize discovery outcomes and research effectiveness.

Mexican research companies prioritize cost-effectiveness and research quality in animal model development, creating demand for premium model systems with advanced features, including research optimization integration and pharmaceutical research systems. The market benefits from established research infrastructure and a willingness to invest in biomedical technologies that provide long-term research benefits and compliance with international pharmaceutical and research standards. Premium research applications, pharmaceutical systems, and discovery programs drive diversified demand across multiple research segments.

Market Intelligence Brief:

• Research market focuses on cost-effectiveness and research quality compliance, driving premium segment growth
• Research partnerships providing 48% faster development cycles
• Technology collaboration between Mexican research companies and international animal model providers
• Research training programs expanding animal model system integration in pharmaceutical and biomedical scenarios

Germany Emphasizes Research Excellence

Germany demonstrates steady market development with a 6.3% CAGR, distinguished by research institutions' preference for high-quality animal models that integrate seamlessly with existing pharmaceutical systems and provide reliable long-term performance in specialized research applications. The market prioritizes advanced features, including precision genetic control, research durability, and integration with comprehensive pharmaceutical platforms that reflect German research expectations for scientific sophistication and operational excellence.

Growth drivers encompass pharmaceutical research optimization applications, expanding biomedical requirements, and advanced research system integration. German researchers emphasize quality control systems and comprehensive scientific documentation that align with domestic research standards. The convergence of advanced genetic technology, pharmaceutical research presence, and traditional scientific heritage creates diversified demand across multiple research segments.

Market Characteristics:

• Premium focus on mice systems with advanced genetic capabilities and precision research features
• Integration requirements with existing pharmaceutical and research platforms
• Emphasis on research reliability and long-term scientific benefits in pharmaceutical applications

France Shows Biomedical Development

France demonstrates steady expansion at 6.2% CAGR through diversified demand from research programs, pharmaceutical activities, and specialty biomedical projects. Major research hubs in regions throughout the country drive animal model adoption for pharmaceutical and specialty biomedical research. Scientific heritage and research programs create sustained market demand, while specialty and advanced applications provide additional growth opportunities. Researcher preference for research models and scientific sophistication supports consistent market development.

Market Characteristics:

• Strong scientific heritage and established research culture supporting premium positioning
• Advanced specialty research and pharmaceutical sectors driving demand for high-quality animal models
• Research positioning capabilities and pharmaceutical market presence supporting diversified revenue streams

United Kingdom Demonstrates Research Innovation

The U.K. market maintains strong growth at 6.0% CAGR, driven by research modernization, pharmaceutical development, and biomedical applications. British research facilities and pharmaceutical companies are implementing advanced animal model systems to enhance research capabilities and support discovery operations that align with research regulations and quality standards. Market expansion benefits from research programs that mandate model performance capabilities in pharmaceutical specifications, creating sustained demand where research flexibility and regulatory compliance represent critical requirements.

Strategic Market Indicators:

• Research and pharmaceutical facilities leading adoption with discovery modernization programs requiring advanced animal model systems
• Research programs providing regulatory support for advanced animal model system acquisition
• Regulatory compliance requirements driving demand for certified systems with research operational compatibility
• Specialized pharmaceutical and research segments adopting comprehensive animal model solutions for discovery optimization

Japan Shows Technology-Focused Development

Japan maintains steady expansion at 5.8% CAGR, distinguished by research institutions' preference for high-quality animal models that integrate seamlessly with existing pharmaceutical systems and provide reliable long-term performance in specialized research applications. The market prioritizes advanced features, including precision genetic control, research quality, and integration with comprehensive pharmaceutical platforms that reflect Japanese research expectations for scientific sophistication and research excellence.

High-specification pharmaceutical and research applications drive demand, supported by advanced genetic research and development initiatives. Japanese researchers emphasize model quality, consistent performance characteristics, and comprehensive scientific documentation that aligns with stringent research standards. The focus on advanced applications and scientific excellence supports stable growth despite regulatory complexity.

Market Characteristics:

• Technology focus on oncology systems with advanced genetic capabilities and precision research features
• Integration requirements with existing pharmaceutical and research platforms
• Emphasis on research reliability and long-term scientific benefits in pharmaceutical applications

South Korea Emphasizes Biotechnology Innovation

South Korea maintains robust development at 5.9% CAGR through biotechnology expansion, pharmaceutical growth, and research applications. Korean biotechnology facilities and pharmaceutical companies are implementing advanced animal model systems to enhance research capabilities and support discovery operations that align with research regulations and quality standards. Market expansion benefits from government biotechnology programs that mandate model performance capabilities in pharmaceutical specifications, creating sustained demand where research flexibility and regulatory compliance represent critical requirements.

Strategic Market Indicators:

• Biotechnology and pharmaceutical facilities leading adoption with research modernization programs requiring advanced animal model systems
• Government biotechnology programs providing regulatory support for advanced animal model system acquisition
• Regulatory compliance requirements driving demand for certified systems with international research compatibility
• Specialized pharmaceutical and biotechnology segments adopting comprehensive animal model solutions for research optimization

Europe Market Split by Countries

The animal model market in Europe is projected to grow from USD 840.0 million in 2025 to USD 1.53 billion by 2035, registering a CAGR of 6.2% over the forecast period. Germany is expected to maintain its leadership position with a 29.8% market share in 2025, increasing to 30.3% by 2035, supported by its advanced research infrastructure, comprehensive pharmaceutical capabilities, and major research facilities serving European and international markets.

France follows with a 24.5% share in 2025, projected to reach 24.9% by 2035, driven by established scientific heritage, research programs, and pharmaceutical sophistication, supported by growing biomedical research trends. United Kingdom holds a 21.4% share in 2025, expected to reach 21.8% by 2035, supported by research modernization and pharmaceutical development. Netherlands commands a 12.1% share in 2025, projected to reach 11.9% by 2035, while Spain accounts for 8.7% in 2025, expected to reach 8.5% by 2035. The Rest of Europe region is anticipated to maintain momentum, with its collective share from 3.5% to 2.6% by 2035, attributed to increasing pharmaceutical research development across Eastern European countries and growing biomedical research across various European markets implementing research programs.

Competitive Landscape of the Animal Model Market

The animal model market is characterized by competition among established research service providers, specialized breeding companies, and integrated CRO organizations. Companies are investing in advanced genetic engineering research, breeding technology development, service integration, and comprehensive portfolios to deliver reliable, precise, and compliant animal model solutions. Innovation in genetic modification methods, breeding technologies, and research service capabilities is central to strengthening market position and competitive advantage.

The Jackson Laboratory leads the market with an 11.0% market share, offering specialized animal model production with a focus on genetic precision and research excellence design for pharmaceutical research operations. Charles River provides comprehensive research services with an emphasis on integrated solutions, breeding innovation, and global research support. Envigo delivers diverse animal model offerings with a focus on regulatory compliance and specialty research capabilities.

Taconic specializes in genetically modified models with emphasis on custom solutions and research optimization. GemPharmatech focuses on Asian markets with specialized genetic engineering and research service capabilities. InVivos offers research solutions with emphasis on European leadership and breeding excellence. Janvier Labs provides model services with French market positioning and research quality.

The competitive landscape is evolving as companies invest in advanced genetic technologies, specialized research services, and global expansion strategies. Market leaders are differentiating through genetic precision, research reliability, and comprehensive service platforms. Innovation in breeding efficiency, genetic enhancement, and research integration drives competitive positioning, while strategic partnerships with pharmaceutical companies and research institutions support market expansion and technology development initiatives.

Key Players in the Animal Model Market

• The Jackson Laboratory (JAX)
• Charles River Laboratories International Inc.
• Envigo RMS LLC
• Taconic Biosciences, Inc.
• GemPharmatech Co., Ltd.
• InVivos Pte. Ltd.
• Janvier Labs
• Crown Bioscience, Inc.
• Xenograft Model Systems LLC
• Hera BioLabs Inc.

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 2.8 Billion
Species	Mice, Rats, Zebrafish/others
Application	Oncology, CNS/metabolic, Others
Service	Breeding, CRO studies, Custom/others
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Countries Covered	United States, Canada, Germany, United Kingdom, France, Japan, South Korea, Mexico, China and 40+ countries
Key Companies Profiled	The Jackson Laboratory, Charles River, Envigo, Taconic, GemPharmatech, InVivos, and Janvier Labs
Additional Attributes	Revenue by species and application category, regional demand trends, competitive landscape, technological advancements in genetic engineering systems, breeding development, research innovation, and service optimization

Animal Model Market by Segments

• Species :

  • Mice
  • Rats
  • Zebrafish/Others

• Application :

  • Oncology
  • CNS/metabolic
  • Others

• Service :

  • Breeding
  • CRO studies
  • Custom/others

• Region :

  • North America

    • United States
    • Canada
    • Mexico

  • Europe

    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe

  • Asia Pacific

    • China
    • Japan
    • India
    • South Korea
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia Pacific

  • Latin America

    • Brazil
    • Chile
    • Rest of Latin America

  • Middle East & Africa

    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Union
    • Rest of Middle East & Africa